Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Profesionales de la salud / / / /
A Randomized Phase III Trial Comparing Bexarotene/Carboplatin/Paclitaxel vs. Carboplatin/Paclitaxel in Chemotherapy-Naive Patients with Advanced or Metastatic NSCLC (SPIRIT II Trial)
Presenter: G.R. Blumenschein, Jr., MDPresenter's Affiliation: SPIRIT II Trial GroupType of Session: ScientificBackground High RXR-beta expression has been shown to be correlated with increased survival in patients with non-small cell lung cancer...
A randomized, double-blind, placebo controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1).
Presenter: J.R. HechtPresenter's Affiliation: UCLA School of Medicine, Los Angeles, CaliforniaType of Session: PlenaryBackground - A potential method for inhibiting tumor growth is to block a tumor's production of blood vessels (angiogenesis)...
Comparison of BEACOPP and ABVD chemotherapy in intermediate stage Hodgkin's lymphoma: Results of the fourth interim analysis of the HD11 trial of the GHSG
Presenter: B.C. KlimmPresenter's Affiliation: German Hodgkin's Study Group (GHSG)Type of Session: ScientificBackground - Combined modality therapy with 4-6 cycles ABVD and Involved Field Radiation (IFRT) is the standard of care for early, unfavorable...
E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer
Presenter: L.J. GoldsteinPresenter's Affiliation: Fox Chase Cancer Center, Philadelphia, PennsylvaniaType of Session: KeynoteBackground A number of recent studies have shown the benefit of taxane based chemotherapy given in combination with other...
Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Cancada Clinical Trials Group (NCIC-CTG)
Presenter: M.J. MoorePresenter's Affiliation: NCICType of Session: PlenaryBackground Advanced and metastatic pancreatic cancer has an extremely poor prognosis, with median survival times between 4-6 months. Multiple attempts at combination...
First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable of unfavorable early stage Hodgkin's lymphoma (HL)
Presenter: E.M. NoordijkPresenter's Affiliation: EORTCType of Session: ScientificBackground Hodgkin's lymphoma (HL) has an excellent prognosis, yet optimal therapy has still yet to be found Patients are treated based on known prognositc factors...
Gene expression profiles predict pathologic complete response to preoperative chemotherapy with gemcitabine, epirubicin, and docetaxel in primary breast cancer.
Presenter: A. SchneeweissPresenter's Affiliation: German Cancer Research Center, Heidelberg, GermanyType of Session: ScientificBackground - One of the benefits of using preoperative chemotherapy for...
HD10: Investigating reduction of combined modality treatment intensity in early stage Hodgkin's Lymphoma. Interim analysis of a randomized trial of the German Hodgkin's Study Group (GHSG)
Presenter: V. DiehlPresenter's Affiliation: German Hodgkin's Study GroupType of Session: ScientificBackground Patients with early stage Hodgkin's lymphoma (HL) have an excellent prognosis This is especially true in patients without risk factors,...
High-dose bevacizumab improved survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200
Presenter: Bruce GiantonioPresenter's Affiliation: University of PennsylvaniaType of Session: PlenaryBackground Bevacizumab (BEV) is a recombinant humanized monoclonal antibody which binds VEGF A. Half life is 17-21 days. 40-60% of...
Long-term survival results of a randomized multinational phase 3 trial of dacarbazine (DTIC) with or without Bcl-2 antisense (oblimersen sodium) in patients with advanced malignant melanoma
Presenter: J.M. KirkwoodPresenter's Affiliation: University of Pittsburgh Cancer InstituteType of Session: ScientificBackground Oblimersen sodium (Genasense, G3139) is an antisense oligonucleotide that selectively targets and specifically...
Molecular Analysis of the IDEAL/INTACT trials: EGFR Mutations and Gene Amplification
Presenter: T.J. LynchPresenter's Affiliation: Massachusetts General Hospital Cancer CenterType of Session: ScientificBackground Previous studies have shown that patients with non-small cell lung cancer (NSCLC) who have mutations in the gene for...
Paclitaxel and gemcitabine vs. carboplatin and gemcitabine. A multicenter, phase III randomized trial in patients with advanced inoperable non-small cell lung cancer (NSCLC)
Presenter: P.A. KosmidisPresenter's Affiliation: Hellenic Cooperative Oncology GroupType of Session: ScientificBackground Early phase data has shown the combination of paclitaxel and gemcitabine may be as active and well tolerate as the...
Randomized phase II/III trial of paclitaxel (P) plus carboplatin with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599
Presenter: A.B. SandlerPresenter's Affiliation: Easteran Cooperative Oncology GroupType of Session: PlenaryBackground The standard therapy for patients with advanced NSCLC is platinum-containing doublet chemotherapy. Randomized trials of targeted...
Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC).
Presenter: B. EscudierPresenter's Affiliation: Institut Gustave Roussy, Villejuif, FranceType of Session: ScientificBackground - Sorafenib (BAY 43-9006) is an oral inhibitor of a number of tyrosine...
Statins reduce the incidence of lung cancer: A study of half a million U.S. veterans.
Presenter: V. KhuranaPresenter's Affiliation: VA Medical Center, Shreveport, LouisianaType of Session: ScientificBackground - Statins (HMG CoA reducatse inhibitors) are a widely studied, effective class...
Endocrine System Cancers
Head and Neck Cancers
Urinary Tract Cancers
Bone Marrow Transplants
General Treatment Concerns
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
Cancer Resource List
Resources for Young Adults